Evoke Pharma, Inc. reiterates revenue guidance for 2024. The company reiterated net revenue guidance in 2024 of approximately $14 million. Evokes 2024 guidance is dependent on its current business and expectations, including recent growth rates in net sales, assumptions regarding reimbursements and prescription fills, as well as factors that are outside of control, such as the global macroeconomic and geopolitical environment, continued supply chain constraints and inflationary pressures.